Welcome to our dedicated page for Medtronic news (Ticker: MDT), a resource for investors and traders seeking the latest updates and insights on Medtronic stock.
Medtronic plc (NYSE: MDT) is a Galway, Ireland-based healthcare technology company whose news flow reflects its broad activity in medical devices, diabetes technology, surgical robotics, and cardiovascular therapies. Company announcements frequently highlight regulatory milestones, clinical evidence, product launches, capital markets activity, and corporate governance developments that matter to investors and healthcare professionals following MDT stock.
Recent news has featured U.S. Food and Drug Administration clearances for key technologies, including the Hugo robotic-assisted surgery (RAS) system for urologic procedures and the MiniMed Go Smart Multiple Daily Injection (MDI) system, which connects the InPen smart insulin pen and the Instinct sensor made by Abbott through the MiniMed Go app. Medtronic has also reported on the broad U.S. commercial launch of the MiniMed 780G automated insulin delivery system integrated with the Instinct sensor, expanding its diabetes technology ecosystem.
Investors can also track Medtronic’s cardiovascular and hypertension-related developments, such as the final National Coverage Determination from the U.S. Centers for Medicare & Medicaid Services for the Symplicity Spyral renal denervation system, and updates on growth drivers like pulsed field ablation and other cardiovascular therapies discussed in earnings releases. Financial news includes quarterly earnings reports, guidance updates, dividend declarations, and details of senior notes offerings and redemptions.
This MDT news page aggregates coverage of topics including diabetes business developments (such as the planned MiniMed IPO registration), conference presentations, leadership and board changes, and major clinical or reimbursement milestones. Readers interested in Medtronic’s role in chronic disease management, minimally invasive surgery, and global healthcare technology can use this page to follow ongoing announcements and review the company’s evolving strategic priorities over time.
Medtronic has launched the ELITE study, a prospective, multicenter trial aimed at confirming the long-term safety and efficacy of its InterStim™ Micro system for treating overactive bladder, fecal incontinence, and non-obstructive urinary retention. The study will enroll 160 patients across 40 sites globally, assessing patient-reported outcomes and quality of life over two years. The InterStim Micro received FDA approval on August 3, 2020, and is positioned as the gold standard in sacral neuromodulation therapy, potentially addressing the needs of millions of patients suffering from bladder and bowel issues.
Medtronic announced the publication of results from the IN.PACT AV Access trial in The New England Journal of Medicine, highlighting the efficacy of the IN.PACT™ AV drug-coated balloon (DCB) for patients with end-stage renal disease (ESRD). The trial involved 330 subjects across three countries and demonstrated a significant reduction in the need for reinterventions—56% fewer than standard treatments—while maintaining a higher primary patency rate (82.2% vs. 59.5%). The study emphasizes the potential for improved patient quality of life and reduced healthcare costs.
Medtronic plc (NYSE: MDT) is set to announce its financial results for the first quarter of fiscal year 2021 on August 25, 2020. The results will be communicated through a news release at approximately 5:45 a.m. CDT, covering the period ending July 31, 2020. A webcast will follow at 7:00 a.m. CDT to discuss these results, accessible at http://investorrelations.medtronic.com/. Additionally, Medtronic plans to report subsequent quarterly results on November 24, 2020, February 23, 2021, and May 27, 2021.
Medtronic announced the first implant of its FDA-approved InterStim Micro neurostimulator for sacral neuromodulation (SNM) therapy at Cleveland Clinic. This device, the smallest rechargeable SNM system, enhances bladder and bowel control for over 55 million Americans suffering from overactive bladder (OAB) and fecal incontinence (FI). Key features include a quick recharge time under an hour, a battery life of 15 years, and MRI compatibility without impedance checks, aimed at improving patient quality of life.
Medtronic has announced a friendly cash tender offer to acquire Medicrea for €7.00 per share, marking a 22% premium over the last closing price. This acquisition aims to enhance Medtronic’s spine surgery capabilities by integrating Medicrea's AI-driven surgical planning and personalized implants. The transaction, supported by major Medicrea shareholders representing 44.4% of its share capital, is expected to close by the end of 2020, pending regulatory approvals. Analysts forecast the deal will be immaterial to Medtronic's adjusted earnings in the initial two years, turning accretive in fiscal year 2023.
Medtronic announced FDA clearance and CE Mark approval for its new LINQ II™ insertable cardiac monitor (ICM), enhancing remote programming capabilities for improved patient management. This device boasts a longevity of 4.5 years and heightened accuracy in detecting abnormal heart rhythms. Notably, it enables clinicians to adjust settings without in-person visits, addressing COVID-19 challenges. LINQ II offers streamlined workflows, reducing time spent on ICM transmissions by 33%, and enhances patient experience through options like smartphone integration.
Medtronic plc (MDT) has launched a significant global post-market study named DISSECT-N to assess the safety and effectiveness of the Valiant Navion™ Thoracic Stent Graft System in treating thoracic aortic dissection. The study will enroll at least 200 patients across 45 sites in North America, Europe, and Asia Pacific, with a primary focus on technical procedure success and major adverse events within one month post-procedure. This initiative responds to a critical need in treating aortic dissection, aiming to provide valuable real-world evidence and improve patient outcomes.
Medtronic reports significant three-year outcomes from the Global SYMPLICITY Registry, demonstrating that renal denervation (RDN) with the Symplicity™ System leads to substantial and lasting reductions in blood pressure (BP) for hypertensive patients. Office systolic BP decreased by 17 mmHg, with two-thirds of patients initially over 180 mmHg achieving lower BP levels. These results, achieved while patients remained on an average of four anti-hypertensive medications, underscore RDN's efficacy and safety, with a renal artery stenosis incidence of only 0.3%.
Medtronic announces FDA approval for the Percept™ PC Deep Brain Stimulation (DBS) system, incorporating BrainSense™ technology. This innovation allows for chronic capture of brain signals while delivering therapy for conditions like Parkinson's disease and OCD. The device, first implanted at Mayo Clinic, enables personalized treatment through data-driven insights. Key features include MRI compatibility, smart battery, improved longevity, and enhanced patient programming. Medtronic aims to transform care standards with this groundbreaking technology.
Medtronic announces the CE mark approval for its Evolut TAVI system to treat severe aortic stenosis in low-risk patients, now including those with bicuspid aortic valves. This new indication allows treatment for patients at extreme, high, and intermediate risks of surgical mortality. The Evolut Low Risk Trial showed TAVI's safer profile and effective outcomes, with shorter hospital stays and improved quality-of-life scores. With over 500,000 annual cases of severe aortic stenosis in Western Europe, this approval significantly increases patient access to minimally invasive valve replacement options.